Abbott Laboratories, (ABT) Fair Value & Analysis
Healthcare · US · Market cap $151B
Abbott Laboratories,
ABT · US
Fair value as of: Jun 24, 2026
From 26 valuation models · updated 8 days ago
Fair value updated Jun 24, 2026 — revised from $78.63 to $79.67 (+1.3%) since Jun 23, 2026. Share price +9.7% over the past month.
Price vs Fair Value (12 months)
12‑month range $78.35 – $127.62 · fair‑value band $51.53 – $103.00 · the $90.53 price screens above the $79.67 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Abbott Laboratories, (ABT) currently trades at $90.53, while our model-based Fair Value estimate is $79.67 — implying the stock looks roughly 12.0% overvalued today. We read business quality at 63/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Abbott Laboratories, generated revenue of $45.1B at a net margin of 13.9%. Revenue grew 7.8% year over year. It earns a return on equity of 12.3%. Net debt stands at $6.5B. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Abbott Laboratories, reported revenue of $44.3B in FY2025 versus $43.1B in FY2021, a compound +0.7%/yr. Reported net income was $6.5B in FY2025, compounding −2.0%/yr from FY2021.
Is ABT fairly valued? → Check now
Recent news
- Abbott (ABT) Stock Falls Amid Market Uptick: What Investors Need to Know
- Sector Update: Healthcare Stocks Higher Late Afternoon
- Global Hematologic Malignancies Testing Market Size/Share Worth USD 12.47 Billion by 2035 at a 14.4% CAGR: Healthcare Foresights (Analysis,
- Edwards Lifesciences Can Sustain Strong Revenue Growth on Technological Leadership, RBC Says
External third-party headlines (Yahoo Finance, Reuters and others) — not an editorial selection, not financial advice.
Similar stocks
6 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Stryker Corporation S1YK34 | R$79.21 | R$43.74 | -45% |
| Medtronic plc MDT | $81.67 | $60.02 | -27% |
| Boston Scientific Corporation B1SX34 | R$229.30 | R$43.33 | -81% |
| Edwards Lifesciences Corporation EW | $85.98 | $41.02 | -52% |
| Siemens Healthineers AG SEMHF | $40.29 | $47.96 | +19% |
| GE HealthCare Technologies Inc GEHC | $61.99 | $48.34 | -22% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Abbott Laboratories, (ABT) undervalued?
What is the fair value of ABT?
What is the quality score of ABT?
What is the revenue of Abbott Laboratories, (ABT)?
What is the net profit margin of ABT?
Does Abbott Laboratories, pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.